ISA TanTec to Acquire Auburn Leather Lace Business
ISA TanTec is pleased to announce that it has signed definitive agreements to acquire the Auburn Leather brand, business and assets with closing in Q2 2018.
Key Auburn staff, including Lisa Howlett, will be retained to ensure continued high quality, character and consistency of the Auburn leather laces for which they are known throughout the industry. Auburn laces will be manufactured in ISA TanTec’s facilities using the same proprietary processes, hides, chemicals and equipment to ensure the authenticity and uniqueness of Auburn’s leather laces continues for our customers.
Auburn was established in 1863 and is the global leader in leather laces. Lisa Howlett, Auburn’s longstanding owner, will join the ISA team as the Auburn Brand Ambassador and will assist in taking the company to the next level by integrating Auburn into the ISA TanTec Group. The integration will create more value through an optimized supply chain as well as using a common sales and marketing structure on a global basis to better serve our clients.
ISA TanTec, the eco-friendly leather manufacturer, known for its LITE (Low Impact To the Environment) Trademark is majority owned by its founder, management, and Navis Capital partners, one of the largest private equity firms in Asia.
ISA Tantec Limited
CEO ISA TanTec
Tel. no. (Macau): +853-6283-2473
Tel. no. (China): +86-138-2707-3388
Tel. no. (Hong Kong):+852-9607-0930
Fax no.: +853-2835-6319
Avenida Da Praia Grande N 619
Comercial Si Toi 5 Andar 8, Macau
Marketing and Public Relations Manager ISA TanTec
Tel. no. (Macau): +853-6263-0008
Fax no.: +853-2835-6319
Avenida Da Praia Grande N 619
Comercial Si Toi 5 Andar 8, Macau
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TeleSign Helps Skype Screen Robocalls with Score3.6.2020 19:00:00 EEST | Press release
TeleSign today announced a new partnership with Microsoft’s Skype to screen robocalls using the flagship digital identity solution Score. By implementing Score, Skype is able to action against calls that are likely of a fraudulent origin. In this capacity Score is able to behave as an inbound spam filter while also preventing other types of communication fraud such as International Revenue Share Fraud (IRSF). Since implementing the TeleSign solution, Skype has been able to action upon over one million fraudulent calls per day. Ravish Patel, Sr. Director Digital Identity Solutions, said, “Robocalling has caused a major customer experience issue for end-users and causes severe reputational damage for communication apps and services who are unaware of the point and scale of such sophisticated attacks. By leveraging a global network consortium and Score's supervised machine learning algorithm, we are able to analyze and effectively flag fraudulent incoming calls, thereby saving money and p
Verimatrix COO Joins Forbes Technology Council3.6.2020 18:45:00 EEST | Press release
Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that COO Asaf Ashkenazi, a recognized expert in cybersecurity, joined the Forbes Technology Council. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005395/en/ Asaf Ashkenazi, Chief Operating Officer at Verimatrix (Photo: Verimatrix) Providing a large-scale venue for Ashkenazi to publish professional insights into protecting everything from content to devices and applications, the Forbes Technology Council is a turn-to source for deep knowledge in the industry. “With the opportunity to work with some of the top minds in cybersecurity and anti-piracy, I look forward to sharing my experiences and insights through the Forbes Technology Council,” Ashkenazi said. “It’s a fitting community to explore the latest achievements and challenges in securing today’s highly distributed digital
Media Alert: ESG Event for Board Directors Featuring CEO of Bank of America and Founder of World Economic Forum Explores Measurement of Stakeholder Capitalism3.6.2020 18:45:00 EEST | Press release
As companies continue to focus on long-term value creation in the face of economic recovery, operationalizing Environmental, Social, and Governance (ESG) will be critical. However, with no consistent metrics, disclosures or reporting frameworks, companies and board members struggle to effectively oversee risk, communicate performance, and measure shareholder and stakeholder impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005677/en/ Join a panel of global business leaders as the discuss what's next for ESG reporting. (Photo: Business Wire) Hear directly from the business leaders who are actively seeking to formalize common metrics and how board members can support initiatives for consistent ESG standards. Featuring Brian Moynihan, Chairman & CEO of Bank of America and Chair of the World Economic Forum International Business Council, and Klaus Schwab, Founder & Executive Chairman of the World Economic Forum, “Meas
IDEMIA and Sopra Steria Chosen by eu-LISA to Build the New Shared Biometric Matching System (sBMS) for Border Protection of the Schengen Area3.6.2020 16:43:00 EEST | Press release
The European Union Agency for the Operational Management of Large-Scale IT Systems in the Area of Freedom, Security and Justice (eu-LISA) has awarded a consortium of IDEMIA and Sopra Steria a framework contract for the delivery of a new shared biometric matching system (sBMS). By 2022, the sBMS will be one of the largest biometric systems in the world, integrating a database of over 400 million third-country nationals with their fingerprints and facial images. Based on European biometrics technology, this new system will first serve the identification needs of the new European Entry/Exit System, thus being the cornerstone of the protection of European borders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005529/en/ (Photo: Business Wire) The contract was awarded following a competitive call for tender (LISA/2019/RP/05 EES BMS and sBMS) by eu-LISA. Its duration is four years, with an option for an extension of up to s
Pierre Fabre Receives European Approval for BRAFTOVI® (encorafenib) in Combination With Cetuximab for the Treatment of Adult Patients With BRAFV600E-Mutant Metastatic Colorectal Cancer3.6.2020 16:08:00 EEST | Press release
Intended for international media only/not intended for UK- and US-based media This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005490/en/ Pierre Fabre today announced that the European Commission (EC) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as Erbitux®) for the treatment of adult patients with BRAFV600E -mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.1 This approval is based on data from the Phase 3 BEACON CRC trial.1,2 The EC decision is applicable to all 27 EU member states plus Iceland, Liechtenstein, Norway and the United Kingdom.3 “This approval is truly great news and much needed for patients with BRAFV600E -mutant mCRC and for physicians treating this devastating cancer, as until now, there has been no EC-approved therapies specifically indicated for this high-medical-need population,” said Josep Tabernero, MD, PhD, BEACON CRC trial lead inv
New First-in-Class Phase 3 TREMFYA®▼ (guselkumab) Data Demonstrate Improvement in Psoriatic Arthritis Joint and Skin Symptoms at Week 523.6.2020 15:28:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2, which showed that TREMFYA® ▼ (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA).1,2 Guselkumab is currently not licensed for the treatment of PsA and is undergoing evaluation for this use by the European Medicines Agency (EMA). Data from the two studies in the DISCOVER programme formed the basis of the validated filing on 11 October 2019 to the EMA in the European Union (EU) for approval of guselkumab for the treatment of adult patients with active PsA and primary endpoint results were recently published in The Lancet.3,4,5 “Those who are living with active psoriatic arthritis are faced with debilitating symptoms and inflammation which
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom